Printer Friendly

GLAXO INC. AND KABI PHARMACIA ANNOUNCE AGREEMENT

 GLAXO INC. AND KABI PHARMACIA ANNOUNCE AGREEMENT
 RESEARCH TRIANGLE PARK, N.C., Oct. 27 /PRNewswire/ -- Glaxo Inc. and


Kabi Pharmacia announced today an agreement that gives Glaxo's dermatology division the U.S. marketing rights to a screening and diagnostic test for allergic contact dermatitis.
 The diagnostic tool, known as True Test(TM), was developed by Kabi Pharmacia to provide convenience and accuracy for physicians seeking to test their patients for a variety of contact allergens.
 It involves the application of two small adhesive strips each containing 12 of the most common contact allergens. Innovative design of the test strips allow controlled exposure to small amounts of the allergens, providing the physician with a "road map" to the source of the allergic response.
 Contact dermatitis is one of the most common skin diseases in industrialized countries, with 2 to 3 percent of the population visiting the physician annually for diagnosis and treatment.
 Under the agreement, Kabi Pharmacia retains marketing rights to the test in Europe, Australia and New Zealand. Glaxo Dermatology, a division of Research Triangle Park, N.C.-based Glaxo Inc., has the right to market the device in the United States. Glaxo also has the right to market the product in all other parts of the world. Manufacture will continue to be the responsibility of Kabi Pharmacia. Specific terms of the agreement were not revealed.
 A product license application for the test, which would be marketed to physicians, is under review at the U.S. Food and Drug Administration, Glaxo said.
 Kabi Pharmacia, located in Uppsala, Sweden, said the agreement represents an important element in its strategy of concentrating its operations in selected fields of medicine. Glaxo Inc., the U.S. subsidiary of London-based Glaxo Holdings p.l.c., also said the agreement fit well with its strategic direction in providing products answering the needs of dermatology patients and their doctors.
 -0- 10/27/92
 /CONTACT: Rick Sluder of Glaxo Inc., 919-248-2839, or Peter Aberg, 46-18-165960, or Carl Johan Wachtmeister, 46-18-163006, both of Kabi Pharmacia/
 (GLX) CO: Glaxo Inc.; Kabi Pharmacia ST: North Carolina IN: MTC SU: JVN


CM -- CH001 -- 5185 10/27/92 08:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1992
Words:358
Previous Article:CURTICE BURNS REPORTS FIRST QUARTER FISCAL 93 SALES AND EARNINGS
Next Article:PHARMACEUTICAL CARE CONFERENCE TO BE HELD OCT. 29 AND 30
Topics:


Related Articles
KABI PHARMACIA TO MARKET SUPRANE, ANAQUEST'S NEW ANESTHETIC, IN EUROPE
ATP POSTS FIGURES FOR FIRST SIX MONTHS
KABI SIGNS CONSENT DECREE WITH FDA,
PROCORDIA ANNOUNCES NEW HEALTH CARE ORGANIZATION IN THE U.S.
READY-TO-APPLY ALLERGEN PATCH TEST CLEARED FOR PATIENT USE
ImClone Systems, Inc. to Present Data on Therapeutic Anti-Angiogenic Antibodies at Anti-Cancer Drug Discovery & Development Summit, June 12 & 13 In...
NeoPharm and Pharmacia settle cancer patent arbitrations.
NeoPharm and Pharmacia Settle Delaware Lawsuits.
NeoPharm to Resume Clinical Trials With LEP.
NeoPharm Terminates License Agreement With Pharmacia.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters